Drug Database
Back to search

Netherlands· NL-d5cde0efb91c

Imlygic 106 plaquevormende eenheden (PFU)/ml oplossing voor injectie

A talimogene laherparepvec product containing talimogeen laherparepvec, registered in Netherlands by Amgen Europe B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC L01XL02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedImlygic 106 plaquevormende eenheden (…ATCL01XL02REGISTER NO.NL-d5cde0efb91cPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about talimogeen laherparepvecAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Talimogene laherparepvec is registered in 11 of 19 countries.

Countries holding a registration under ATC L01XL02 (talimogene laherparepvec), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search talimogene laherparepvec products by name

Talimogene laherparepvec · ATC L01XL02

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
TALIMOGEEN LAHERPAREPVEC
Manufacturer
Amgen Europe B.V.
Country
Netherlands (NL)
ATC code
L01XL02
ATC class
Talimogene laherparepvec
Defined daily dose
0.14 DE, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/15/1064

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

289 interactions on record for talimogene laherparepvec.

Graded by severity as the source publishes them — 284 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check talimogene laherparepvec against other medicinesHow interaction checks work

Talimogene laherparepvec · interactions on record

289 records

  • 284 severe
  • 5 moderate

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Talimogene laherparepvec in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All talimogene laherparepvec products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Imlygic
  • Norway · Imlygic

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2ab22062-19a4-41c2-978d-9787d1bf1562
GET /v1/drugs/2ab22062-19a4-41c2-978d-9787d1bf1562?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Intralaesionaal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/imlygic-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Talimogene Laherparepvec",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp116355",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 2-WATER (E 339)",
    "MYO-INOSITOL",
    "NATRIUMCHLORIDE",
    "NATRIUMDIWATERSTOFFOSFAAT 2-WATER (E 339)",
    "SORBITOL (E 420)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "TALIMOGEEN LAHERPAREPVEC"
  ],
  "leaflet_url": null,
  "authorised_at": "2015/12/17",
  "procedure_number": "EMEA/H/C/002771",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/15/1064",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about talimogene laherparepvec.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console